Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Envoy Medical Q3 2026 Results: Net Loss of $3.93M, Loss Narrows

For the nine months ended September 30, 2026, Envoy Medical reported a net loss of $14.3 million, an improvement from the $17.2 million loss in the prior year period. The company strengthened its balance sheet through a February 2026 offering, increasing cash to $14.6 million and significantly reducing its stockholders' deficit.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.10.0
Net income-3.9-6.5
EPS (diluted, $ a share)$-0.50$-3.55

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+57.1%
Source

10-Q filed with the SEC, NASDAQ: COCH. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Envoy Medical, Inc.: key numbers

Share price
$6.92Close, Nov 16
Market cap
$53.6M
Shares outstanding
7.74MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Orthopedic, Prosthetic & Surgical Appliances & SuppliesSIC 3842

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Envoy Medical, Inc.

All →
7:14 AM ET 8-K
Financial Results

Envoy Medical Financial Results

Envoy Medical reported third quarter 2026 financial results and provided a clinical update on its Acclaim fully implanted cochlear implant. The company reached a six-month follow-up milestone for its full pivotal trial cohort and submitted the second module of its Modular PMA application to the FDA.

“We continued to make significant progress with our investigational fully implanted cochlear implant during the third quarter, as we approach an extremely exciting 2027. Not only did we report encouraging 12-month data from the first 10 participants in our trial, but we also surpassed the three-month follow-up mark for the full cohort. Since quarter end, we have now surpassed the six-month follow-up milestone. We remain on track for all participants to complete their 12-month visits by early in the second quarter of 2027. Each milestone brings us closer to offering cochlear implant candidates a fully implanted option they have wanted for decades.”

Brent Lucas, Chief Executive Officer of Envoy Medical
8:41 AM ET 8-K
Reverse Stock Split

Envoy Medical Reverse Stock Split

Envoy Medical implemented a 1-for-10 reverse stock split of its Class A common stock, effective October 26, 2026. The split is intended to regain compliance with Nasdaq's $1.00 minimum bid price requirement for continued listing. Every 10 shares of outstanding common stock were automatically combined into one share, with fractional shares settled in cash.

4:30 PM ET 8-K
Reverse Stock Split

Envoy Medical Reverse Stock Split

Envoy Medical stockholders approved an amendment to the certificate of incorporation to authorize a reverse stock split of Class A Common Stock at a ratio between 1-for-5 and 1-for-25. The Board of Directors has the discretion to effect the split at any time on or before December 31, 2026.

9:00 AM ET 8-K
Court & Legal Update

Envoy Medical Court & Legal Update

Envoy Medical entered into a Dismissal Agreement with Atlas Merchant Capital SPAC Fund I LP to resolve litigation in the Delaware Court of Chancery. The litigation concerned allegations that Atlas was not permitted to redeem its shares during the company's September 2023 business combination. All claims will be dismissed with prejudice with no payment required from Envoy Medical or other defendants.

Counterparty
Atlas Merchant Capital SPAC Fund I LP

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.